191 related articles for article (PubMed ID: 30206308)
1. Downregulating Notch counteracts Kras
Kong G; You X; Wen Z; Chang YI; Qian S; Ranheim EA; Letson C; Zhang X; Zhou Y; Liu Y; Rajagopalan A; Zhang J; Stieglitz E; Loh M; Hofmann I; Yang D; Zhong X; Padron E; Zhou L; Pear WS; Zhang J
Leukemia; 2019 Mar; 33(3):671-685. PubMed ID: 30206308
[TBL] [Abstract][Full Text] [Related]
2. Systemic Notch downregulation promotes Kras
You X; Wen Z; Chang YI; Ranheim EA; Zhou Y; Zhou L; Kong G; Zhang J
Br J Haematol; 2019 Aug; 186(3):e52-e56. PubMed ID: 30931528
[No Abstract] [Full Text] [Related]
3. Oncogenic Kras
Hamarsheh S; Osswald L; Saller BS; Unger S; De Feo D; Vinnakota JM; Konantz M; Uhl FM; Becker H; Lübbert M; Shoumariyeh K; Schürch C; Andrieux G; Venhoff N; Schmitt-Graeff A; Duquesne S; Pfeifer D; Cooper MA; Lengerke C; Boerries M; Duyster J; Niemeyer CM; Erlacher M; Blazar BR; Becher B; Groß O; Brummer T; Zeiser R
Nat Commun; 2020 Apr; 11(1):1659. PubMed ID: 32246016
[TBL] [Abstract][Full Text] [Related]
4. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
5. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
6. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
[TBL] [Abstract][Full Text] [Related]
7. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Notch Signaling in Kras-Induced Gastric Metaplasia.
Chung WC; Zhou Y; Atfi A; Xu K
Neoplasia; 2019 Aug; 21(8):810-821. PubMed ID: 31276933
[TBL] [Abstract][Full Text] [Related]
9. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
10. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
[TBL] [Abstract][Full Text] [Related]
11. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
Wen Z; Yun G; Hebert A; Kong G; Ranheim EA; Finn R; Rajagoplan A; Li S; Zhou Y; Yu M; Damnernsawad A; Roose JP; Coon JJ; Wen R; Wang D; Zhang J
Blood; 2021 Jun; 137(23):3259-3271. PubMed ID: 33512434
[TBL] [Abstract][Full Text] [Related]
12. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.
Baumgart A; Mazur PK; Anton M; Rudelius M; Schwamborn K; Feuchtinger A; Behnke K; Walch A; Braren R; Peschel C; Duyster J; Siveke JT; Dechow T
Oncogene; 2015 Jan; 34(5):578-88. PubMed ID: 24509876
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
[TBL] [Abstract][Full Text] [Related]
14. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
Van Meter ME; Díaz-Flores E; Archard JA; Passegué E; Irish JM; Kotecha N; Nolan GP; Shannon K; Braun BS
Blood; 2007 May; 109(9):3945-52. PubMed ID: 17192389
[TBL] [Abstract][Full Text] [Related]
15. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
16. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Diaz-Flores E; Goldschmidt H; Depeille P; Ng V; Akutagawa J; Krisman K; Crone M; Burgess MR; Williams O; Houseman B; Shokat K; Sampath D; Bollag G; Roose JP; Braun BS; Shannon K
Sci Signal; 2013 Dec; 6(304):ra105. PubMed ID: 24300897
[TBL] [Abstract][Full Text] [Related]
17. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
[TBL] [Abstract][Full Text] [Related]
18. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
Melo-Cardenas J; Xu Y; Wei J; Tan C; Kong S; Gao B; Montauti E; Kirsammer G; Licht JD; Yu J; Ji P; Crispino JD; Fang D
Blood; 2018 Jul; 132(4):423-434. PubMed ID: 29844011
[No Abstract] [Full Text] [Related]
19. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
[TBL] [Abstract][Full Text] [Related]
20. Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.
Chung E; Hsu CL; Kondo M
PLoS One; 2011; 6(12):e28350. PubMed ID: 22164275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
